Lanean...
Activity of erlotinib when dosed below maximum tolerable dose for EGFR-mutant lung cancer: implications for targeted therapy development
BACKGROUND: Erlotinib is a standard first-line therapy for metastatic non-small-cell lung cancers (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The recommended dose of 150mg daily is the maximum tolerated dose (MTD). Little clinical data is available regarding its efficacy at doses...
Gorde:
| Argitaratua izan da: | Cancer |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5311035/ https://ncbi.nlm.nih.gov/pubmed/27525836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30270 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|